Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Ratner, Robert ^a   Han, Jenny ^b   Nicewarner, Dawn ^b   Yushmanova, Irina ^b   Hoogwerf, Byron J ^c   Shen, Larry ^b  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

cardiovascular safety; GLP 1 receptor agonistdiabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; VENOM;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIABETIC DIET; DISEASE DURATION; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSULIN TREATMENT; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STROKE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; KAPLAN MEIER METHOD; META ANALYSIS; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIDES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; VENOMS;

EID: 79952694840     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-22     Document Type: Article

References (80)

1. Buse JB, Ginsbert HN, Bakris GL, Clark N, Costa F, Eckel R, Fonseca V, Gerstein H, Grundy S, Nesto R, Pignone MP, Plutzky J, Porte D, Redbert R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007, 30:162-172. 10.2337/dc07-9917, 17192355.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471. 10.1056/NEJMoa072761, 17517853.
3. Cleland JG, Atkin SL. Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet 2007, 370:1103-1104. 10.1016/S0140-6736(07)61488-3, 17905146.
4. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578-581.
5. Mulrow CD, Cornell J, Localio AR. Rosiglitazone: a thunderstorm from scarce and fragile data. Ann Intern Med 2007, 147:585-587.
6. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007, 356:2522-2524. 10.1056/NEJMe078099, 17517854.
7. Rosen CJ. Revisiting the rosiglitazone story--lessons learned. N Engl J Med 2010, 363:803-806. 10.1056/NEJMp1008233, 20660395.
8. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135. 10.1016/S0140-6736(09)60953-3, 19501900.
9. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191-1201.
10. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418. 10.1001/jama.2010.920, 20584880.
11. Nissen SE. Setting the RECORD Straight. JAMA 2010, 303:1194-1195. 10.1001/jama.2010.333, 20332408.
12. Juurlink DN. Rosiglitazone and the case for safety over certainty. JAMA 2010, 304:469-471. 10.1001/jama.2010.954, 20584879.
13. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433. 10.2337/dc09-1499, 2809297, 20103558.
14. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362:774-777. 10.1056/NEJMp1001578, 20164475.
15. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447. 10.1111/j.1463-1326.2006.00602.x, 16776751.
16. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428. 10.1111/j.1463-1326.2006.00589.x, 16776749.
17. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
18. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100. 10.2337/diacare.28.5.1092, 15855572.
19. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091. 10.2337/diacare.28.5.1083, 15855571.
20. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635. 10.2337/diacare.27.11.2628, 15504997.
21. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348. 10.1016/j.clinthera.2007.11.006, 18158075.
22. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, Group F. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
23. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows B, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267. 10.1007/s00125-006-0510-2, 17160407.
24. Zinman B, Hoogwerf BJ, Durán Garcia S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007, 146:477-485.
25. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007, 30:2767-2772. 10.2337/dc06-2532, 17595353.
26. Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, Jang HC, Wu TJ, Johns D, Northrup J, Brodows R. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009, 83:69-76. 10.1016/j.diabres.2008.09.037, 19019476.
27. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009, 56:415-424. 10.1507/endocrj.K08E-296, 19194050.
28. Moretto TJ, Milton DR, Ridge TD, MacConell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460. 10.1016/j.clinthera.2008.08.006, 18803987.
29. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, Braun D, Giaconia J, Malone J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010, 9:6. 10.1186/1475-2840-9-6, 2823663, 20109208.
30. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med 2008, 358:2560-2572. 10.1056/NEJMoa0802987, 18539916, ADVANCE Collaborative Group.
31. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. 10.1016/S0140-6736(98)07019-6, 9742976, UK Prospective Diabetes Study Group.
32. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996, 9:342-360. 10.1016/0895-7061(96)00037-4, 8722437.
33. Farmer JA, Gotto AM. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003, 92:3i-9i. 10.1016/S0002-9149(03)00503-4, 12867249.
34. Scandinavian Simvastatin Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Study Group.
35. ACCORD Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. 10.1056/NEJMoa0802743, 18539917, ACCORD Study Group.
36. Food and Drug Administration Official transcript Endocrinologic and Metabolic Drugs Advisory Committee meeting, April 1, 2009. 2009, Silver Spring, MD, updated 02/17/2010, Food and Drug Administration., http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151169.pdf
37. Food and Drug Administration Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008, Silver Spring, MD, cited 2009 August 27, Food and Drug Administration., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
38. Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med 2007, 26:4375-4385. 10.1002/sim.3060, 17768699.
39. Amato DJ. A generalized Kaplan-Meier estimator for heterogeneous population. Commun Stat Theory 1988, 17:263-286.
40. Ulm K. Simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990, 131:373-375.
41. Ng HKT, Tang ML. Testing the equality of two Poisson means using the rate ratio. Stat Med 2005, 24:955-965. 10.1002/sim.1949, 15532090.
42. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LiveLink database. Diabetes Care 2011, 34:90-95. 10.2337/dc10-1393, 20929995.
43. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. 28659, 9732337, UK Prospective Diabetes Study Group.
44. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-720. 28660, 9732338, UK Prospective Diabetes Study Group.
45. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591. 10.1056/NEJMoa0706245, 18256393.
46. Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med 2004, 47:564-574. 10.1353/pbm.2004.0071, 15467178.
47. UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. 10.1016/S0140-6736(98)07037-8, 9742977, UK Prospective Diabetes Study Group.
48. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. 10.1056/NEJMoa052187, 2637991, 16371630.
49. Holman RR, Paul SK, Bethel AM, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
50. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. 10.1056/NEJM199309303291401, 8366922, Diabetes Control and Complications Trial Research Group.
51. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, Investigators F. Glucose control and vascular complications in veterans with type 2 diabetes. New Engl J Med 2009, 360:129-139. 10.1056/NEJMoa0808431, 19092145.
52. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394-403.
53. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909. 10.1136/bmj.b4909, 2803744, 20061358.
54. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DCJ, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010, 33:983-990. 10.2337/dc09-1278, 20427682.
55. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412. 10.1136/bmj.321.7258.405, 27454, 10938048.
56. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
57. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjörnsdóttir S, Eliasson B. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009, 52:65-73. 10.1007/s00125-008-1190-x, 18985314.
58. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20:1744-1766.
59. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008, 31:173-175. 10.2337/dc08-9016, 18165348.
60. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009, 8:573-584. 10.1517/14740330903081725, 19538102.
61. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
62. Gallwitz B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. Drug Safety 2010, 33:87-100. 10.2165/11319130-000000000-00000, 20082536.
63. Buysschaert M, Preumont V, Oriot PR, Paris I, Ponchon M, Scarnière D, Selvais P, Exenatide F. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. [French]. Diabetes Metab 2010, 36:381-388. 10.1016/j.diabet.2010.03.009, 20598606.
64. Landstedt-Hallin L, Englund A, Adamson U, Lins PE. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999, 246:299-307. 10.1046/j.1365-2796.1999.00528.x, 10475998.
65. Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, Heller SR. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997, 14:648-654. 10.1002/(SICI)1096-9136(199708)14:8<648::AID-DIA418>3.0.CO;2-1, 9272590.
66. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010, 23:334-339. 10.1038/ajh.2009.245, 20019672.
67. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47. 10.1016/S0140-6736(09)60659-0, 19515413.
68. Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Järvinen H, Diamant M, Taskinen MR. One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010, 212:223-229. 10.1016/j.atherosclerosis.2010.04.024, 20494360.
69. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, Taskinen MR, Yki-Järvinen H, Smith U. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010, 33:1734-1737. 10.2337/dc09-2361, 20424219.
70. Anselmino M, Öhrvik J, Rydén L. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart. Eur Heart J 2010, 31:3040-3045. 10.1093/eurheartj/ehq368, 20935002.
71. Stettler C, Bearth A, Allemann S, Zwahlen M, Zanchin L, Deplazes M, Christ ER, Teuscher A, Diem P. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia 2007, 50:186-194. 10.1007/s00125-006-0483-1, 17096116.
72. Linnebjerg H, Seger M, Kothare P, Hunt T, Hons B, Mitchell MI. The effect of exenatide on QTc interval in healthy subjects [abstract]. Diabetes 2009, 58:A161.
73. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961. 10.1161/01.CIR.0000139339.85840.DD, 15313949.
74. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y, Shannon R. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113. 10.1124/jpet.106.100982, 16489128.
75. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151. 10.2337/diabetes.54.1.146, 15616022.
76. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG, Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010, 9:32. 10.1186/1475-2840-9-32, 2922097, 20678234.
77. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, Parkes DG. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010, 9:76. 10.1186/1475-2840-9-76, 2996354, 21080957.
78. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965. 10.1161/01.CIR.0000120505.91348.58, 14981009.
79. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699. 10.1016/j.cardfail.2006.08.211, 17174230.
80. Eldor R, Kidron M, Greenberg-Shushlav Y, Arbit E. Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol 2010, 4:1516-1523.